Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1461-1480 of 3,900 trials

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology

Knee Osteoarthritis: Genicular Arteries Embolization Study

We are investigating whether a new procedure can help reduce knee pain in people with symptomatic knee osteoarthritis. Participants will compare this treatment to a sham procedure to assess its effectiveness.

Knee Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Juvenile Idiopathic Arthritis: Bimekizumab Study

We are studying the safety and how bimekizumab moves in the body for children aged 2 to under 18 with certain types of juvenile idiopathic arthritis. This research aims to help improve treatment options for these young patients.

Juvenile Arthritis and Related Conditions6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePediatricsRheumatology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Metastatic Colorectal Cancer: Tinzaparin for Blood Clot Prevention

We are studying whether tinzaparin can help prevent blood clots in patients with metastatic colorectal cancer starting their first line of treatment. This may help reduce the risk of complications related to blood clots.

Metastatic Colorectal CancerThromboembolic Event>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOncology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diabetic Retinopathy: BI 764524 Treatment Study

We are testing whether the new treatment BI 764524 can improve eye health in people with diabetic retinopathy. The study will compare its effects to a placebo to see if it helps prevent serious vision problems.

Diabetic Retinopathy6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyOphthalmology

Atrial Fibrillation: Rivaroxaban Monotherapy Study

We are exploring the safety of rivaroxaban in patients with atrial fibrillation who have had a heart procedure. This study aims to see if this treatment is a viable option for these patients.

Coronary Artery DiseasePercutaneous Coronary InterventionAtrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Prednisolone Transfer in Breast Milk: A Study for Breastfeeding Mothers

We are investigating how prednisolone, used for inflammation, transfers into breast milk and affects breastfeeding infants. This study aims to measure medication levels in both mothers and their babies to ensure safety.

Rheumatoid ArthritisSystemic Lupus ErythematosusMyositis≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePediatrics

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Childhood Renal Tumors: Comparing Chemotherapy Treatments

We are studying two chemotherapy combinations for children with stage IV renal tumors to see which one works better and has fewer side effects. This research aims to improve treatment outcomes for young patients.

Nephroblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyOncologyPediatrics

Medical Cannabis Aerosol for Diabetic Peripheral Neuropathic Pain

We are studying whether a medical cannabis aerosol can help reduce pain for people with diabetic peripheral neuropathic pain. Participants will compare different doses of THC to a placebo to assess pain relief and quality of life.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Eosinophilic Esophagitis: BP1.7881 Treatment Study

We are testing a new medication, BP1.7881, for adults with eosinophilic esophagitis to see if it can improve their condition. The study will also look at how safe and well-tolerated the treatment is.

Eosinophilic Esophagitis3-6 monthsEfficacy phase (II)≤5 visitsPartially RemoteAllergologyGastroenterology

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Acute Vaginal Infection: BGY-1601-VT Tablet

We are studying a new vaginal tablet for women with acute vaginal infections to see if it works better than a placebo. The trial will help us understand its safety and effectiveness for conditions like Bacterial Vaginosis and Vulvovaginal Candidiasis.

Gynecological Conditions1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInfectious Diseases

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology